logo-loader
viewOpen Orphan Plc

Amryt Pharma co-founder welcomes 'transformational' Aegerion acquisition

Open Orphan PLC (LON:ORPH) chief executive Cathal Friel co-founded Amryt Pharma PLC (LON:AMYT) along with current CEO Joe Wiley and gives his view on the  acquisition of Aegerion Pharmaceuticals Inc.

The merger creates a group with revenues of $136.5mln in 2018 and re-unites the Lojuxta cholesterol treatment under one roof.

Quick facts: Open Orphan Plc

Price: 5.85 GBX

AIM:ORPH
Market: AIM
Market Cap: £14.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan Plc named herein, including the promotion by the Company of Open Orphan Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan 'continuing to target rapid scale-up and profitability'

Proactive Research analyst Emma Ulker says Open Orphan (LON:ORPH) is continuing to target rapid scale-up and profitability in the dynamic European orphan and rare disease consulting sector via acquisitions and organic means. The company’s Venn Life Sciences consulting arm has recently signed...

18 hours, 24 minutes ago

2 min read